Ehsan Nazemalhosseini Mojarad, Peter JK Kuppen. HER2 and immunotherapy using monoclonal antibodies in colorectal cancer.Immunotherapy (2013) 5(12), 1267–1269

There is no doubt that HER2 can be immunogenic

and generate antibodies and activation of

T lymphocytes (including both cytotoxic T cells

and T-helper cells) in vivo [9]. This suggests that

HER2 can also be a target for T cell-directed

immunotherapy, as seems to be possible for other

‘self’ proteins that are overexpressed [19]. For the

large group of patients in CRC that demonstrates

HER2 overexpression, but with the protein

remaining in the cytoplasm, this may be an

attractive option that deserves further study

http://blog.sciencenet.cn/blog-571539-967712.html